Does Laterality of Positive Needle Biopsy in Clinical T2a Patients With Prostate Cancer Affect Biochemical Recurrence-Free Survival?

Urology

Volumn 72, Issue 6, 2008, Pages 1219-1223

  Wu, Ina ^a   Nielsen, Matthew E ^a   Han, Misop ^a   Partin, Alan W ^a   Makarov, Danil V ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE;

ADULT; AGED; BIOPSY, NEEDLE; DISEASE-FREE SURVIVAL; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 56449113270     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.12.089     Document Type: Article

References (11)

1. American Cancer Society. Cancer Facts and Figures 2007. http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf Accessed Mar 9, 2008
2. National Cancer Institute. Prostate cancer treatment: stage information. http://www.cancer.gov/cancertopics/pdq/treatment/prostate/Patient/page2 Accessed Mar 9, 2008
3. Mouraviev V., Mayes J.M., Sun L., et al. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 110 (2007) 906-910
4. Vis A.N., Kranse R., Roobol M., et al. Serendipity in detecting disease in low prostate-specific antigen ranges. BJU Int 89 (2002) 384-389
5. Ghavamian R., Blute M.L., Bergstralh E.J., et al. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. Urology 54 (1999) 105-110
6. Ramos C.G., Carvalhal G.F., Smith D.S., et al. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer. J Urol 161 (1999) 1525-1529
7. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766-771
8. Daniels Jr. G.F., McNeal J.E., and Stamey T.A. Predictive value of contralateral biopsies in unilaterally palpable prostate cancer. J Urol 147 (1992) 870-874
9. Freedland S.J., Presti Jr. J.C., Terris M.K., et al. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database. J Urol 169 (2003) 2129-2135
10. Campbell T., Blasko J., Crawford E.D., et al. Clinical staging of prostate cancer: reproducibility and clarification of issues. Int J Cancer 96 (2001) 198-209
11. Sexton T., Rodrigues G., Brecevic E., et al. Controversies in prostate cancer staging implementation at a tertiary cancer center. Can J Urol 13 (2006) 3327-3334